Concordance of Paired Maternal and Newborn Urine Drug Screens using Low Cutoffs for Positivity
Stephen M. Roper Washington University School of Medicine, St. Louis, MO.
Warning: Undefined variable $headshot in /var/www/html/view_abstract/view_abstract_in_program.php on line 704
Stephen Roper (Presenter) Washington University School of Medicine
Presenter Bio: My research interests include proteomics, inborn errors of metabolism, toxicology, and the development of mass spectrometry-based clinical chemistry assays. My doctoral research was focused on the identification of alternatively-sialylated glycoproteins in non-small cell lung cancer progression and imaging mass spectrometry. Following the completion of my PhD, I pursued a postdoctoral fellowship in clinical chemistry where my research focused on evaluating methods for LDL cholesterol measurement, pharmacogenomic test implementation, and pediatric reference intervals. In August of 2017 I began a position as an Assistant Professor of Pathology at Washington University School of Medicine. Since that time, I have been working on the development and implementation of various mass spectrometry-based clinical assays.
Relevant Financial Disclosures
(within past 24 months)
No relevant financial relationship(s) to disclose.
Abstract
Drug testing maternal and newborn urine near the time of birth is useful to detect substance use in the time period immediately before delivery. However, discrepant results between mom and baby are common and can lead to confusion that delays follow-up interventions. Defining the agreement of compounds identified in these paired specimens may serve as a valuable resource for the end-users of this data. In this study, we applied an in-house developed LC-MS/MS drug screen with low cutoffs for positivity to over 100 paired specimens and identified 5 compounds with very good agreement and 7 compounds with poor agreement.
= Discovery stage. (17.55%, 2019 US)
= Translation stage. (42.72%, 2019 US)
= Clinically available. (39.74%, 2019 US)
